InvestorsObserver
Sign Up Login

TAK Takeda Pharmaceutical Ltd ADR

$13.16 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

TAK Stock Analysis Overview

What this means: Takeda Pharmaceutical Ltd ADR (TAK) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives TAK a rank of 22. Our methodology considers analysis of the company's financial situation and how it has traded recently. TAK rank of 22 means that it ranks below 78% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

TAK Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

TAK Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

TAK Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

TAK Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

TAK Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

TAK Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

TAK Stock Analysis Overview

What this means: Takeda Pharmaceutical Ltd ADR (TAK) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives TAK a rank of 22. Our methodology considers analysis of the company's financial situation and how it has traded recently. TAK rank of 22 means that it ranks below 78% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full TAK report

TAK Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

TAK Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

TAK Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

TAK Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

TAK Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

TAK Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Takeda Pharmaceutical Ltd ADR (TAK) Analyst Forecast

TAK Price, Volume, Earnings, and Dividend Date

  • Last Price $13.16
  • Previous Close $13.16
  • Change $0.00
  • Open $13.16
  • Volume 1,286,645
  • Avg. Volume (100-day) 1,825,974
  • Market Cap 41,293,141,398
  • Days Range 13.12 - 13.225
  • 52-week Range 13.11 - 17.11
  • Dividend Yield 4.85%
  • Ex. Dividend Date 09/28/23
  • P-E 37.93
  • EPS 0.38
  • Earnings Date 05/09/24
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec. Premium
  • Beta 0.385
  • PEG Ratio 3.74

Takeda Pharmaceutical Ltd ADR (TAK) Company Description

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Ltd ADR (TAK) Stock Chart

View Interactive TAK chart

My Watchlists

Top Stocks in Drug Manufacturers - Specialty & Generic